Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h...

ver descrição completa

Detalhes bibliográficos
Autores: Caballero-Bermejo, Antonio F, Darnaude-Ximénez, Ignacio, Aguilar-Pérez, Myriam, Gomez-Lopez, Alicia, Sancho-López, Aránzazu, López García-Gallo, Cristina, Díaz Nuevo, Gema, Diago-Sempere, Elena, Ruiz-Antorán, Belén, Avendaño-Solá, Cristina, Ussetti-Gil, Piedad, PBISA01-Study Group
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16667
Acesso em linha:http://hdl.handle.net/20.500.12105/16667
Access Level:acceso abierto
Palavra-chave:Transplant Recipients
Lung
Humans
Bronchoalveolar Lavage Fluid
Triazoles
Descrição
Resumo:Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.

Registos relacionados